

EV485023385 U.S.

Express Mail Label Number

10-12-04

Date of Deposit

DT03 Rec'd PCT/PTO 12 OCT 2004

Form PTO-1390-MOD (REV 10-96)		U. S. Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER 4-32459A
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	
INTERNATIONAL APPLICATION NO. PCT/EP03/04007	INTERNATIONAL FILING DATE 16 APRIL 2003	10/510969	
TITLE OF INVENTION METHODS TO PREDICT PATIENT RESPONSIVENESS TO TYROSINE KINASE INHIBITORS		PRIORITY DATE CLAIMED 17 APRIL 2002	
APPLICANT(S) FOR DO/EO/US DRESSMAN, ET AL.			

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau. (See Form PCT/IB/308)
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included.

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
 A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information: Application Data Sheet, Unexecuted Declaration

10/510969

DT05 Rec'd PCT/PTO 12 OCT 2004

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER																				
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):		CALCULATIONS PTO USE ONLY																				
Search Report has been prepared by the EPO or JPO International preliminary examination fee paid to USPTO (37 CFR 1.482) No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4). ENTER APPROPRIATE BASIC FEE AMOUNT =		\$920 \$730 \$770 \$1,080 \$100 \$ 920																				
Surcharge of \$130 for furnishing the oath of declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). <table border="1"> <tr> <th>CLAIMS</th> <th>NUMBER FILED</th> <th>NUMBER EXTRA</th> <th>RATE</th> </tr> <tr> <td>Total claims</td> <td>69</td> <td>- 20 =</td> <td>49</td> </tr> <tr> <td>Independent claims</td> <td>16</td> <td>- 3 =</td> <td>13</td> </tr> <tr> <td colspan="3">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$ 290</td> </tr> <tr> <td colspan="3"></td> <td>TOTAL OF ABOVE CALCULATIONS =</td> </tr> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	69	- 20 =	49	Independent claims	16	- 3 =	13	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 290				TOTAL OF ABOVE CALCULATIONS =	\$
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																			
Total claims	69	- 20 =	49																			
Independent claims	16	- 3 =	13																			
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 290																			
			TOTAL OF ABOVE CALCULATIONS =																			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).		\$																				
		SUBTOTAL =																				
Processing fee of \$130 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$ 2,920																				
		TOTAL NATIONAL FEE =																				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$ per property		\$																				
		TOTAL FEES ENCLOSED =																				
		Amount to be: \$ refunded charged \$																				
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$2,920 to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.																						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.																						
Send all correspondence to the address associated with Customer No. 001095, which is currently:  John T. Prince Attorney for Applicants Reg. No. 43,019 (617) 871-3346																						
Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080 Dated: October 12, 2004																						